

Title (en)  
PHARMACEUTICAL COMPOSITION OF 1-(3-HYDROXY-4-METHOXYPHENYL)-4-METHYL-5-ETHYL-7,8-DIMETHOXY-5H-2,3-BENZODIAZEPINE AND USES THEROF

Title (de)  
PHARMAZEUTISCHE ZUSAMMENSETZUNG VON 1-(3-HYDROXY-4-METHOXYPHENYL)-4-METHYL-5-ETHYL-7,8-DIMETHOXY-5H-2,3-BENZODIAZEPIN UND IHRE VERWENDUNG

Title (fr)  
COMPOSITION PHARMACEUTIQUE DE 1-(3-HYDROXY-4-METHOXYPHENYL)-4-METHYL-5-ETHYL-7,8-DIMETHOXY-5H-2,3-BENZODIAZEPINE ET UTILISATIONS DE CELLE-CI

Publication  
**EP 1575521 A4 20080430 (EN)**

Application  
**EP 03815301 A 20031203**

Priority  
• US 0338641 W 20031203  
• US 43077002 P 20021203

Abstract (en)  
[origin: US2004152695A1] Pharmaceutical compositions comprise 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine, or a pharmaceutically acceptable salt thereof. The compositions are used for treating, preventing or delaying the onset of disorders mediated by LTB4 or TXA2.

IPC 8 full level  
**A61K 31/551** (2006.01); **A61P 1/00** (2006.01); **A61P 1/04** (2006.01); **A61P 7/02** (2006.01); **A61P 9/00** (2006.01); **A61P 9/10** (2006.01); **A61P 11/06** (2006.01); **A61P 15/08** (2006.01); **A61P 17/06** (2006.01); **A61P 19/02** (2006.01); **A61P 19/08** (2006.01); **A61P 25/00** (2006.01); **A61P 25/02** (2006.01); **A61P 25/04** (2006.01); **A61P 25/16** (2006.01); **A61P 25/24** (2006.01); **A61P 29/00** (2006.01); **A61P 37/00** (2006.01)

CPC (source: EP US)  
**A61K 31/551** (2013.01 - EP US); **A61P 1/00** (2017.12 - EP); **A61P 1/04** (2017.12 - EP); **A61P 3/02** (2017.12 - EP); **A61P 7/02** (2017.12 - EP); **A61P 9/00** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 11/06** (2017.12 - EP); **A61P 15/08** (2017.12 - EP); **A61P 17/06** (2017.12 - EP); **A61P 19/02** (2017.12 - EP); **A61P 19/06** (2017.12 - EP); **A61P 19/08** (2017.12 - EP); **A61P 21/00** (2017.12 - EP); **A61P 25/00** (2017.12 - EP); **A61P 25/02** (2017.12 - EP); **A61P 25/04** (2017.12 - EP); **A61P 25/16** (2017.12 - EP); **A61P 25/24** (2017.12 - EP); **A61P 25/28** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 31/00** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 37/00** (2017.12 - EP); **A61P 37/04** (2017.12 - EP); **Y02A 50/30** (2017.12 - EP US)

Citation (search report)  
• [X] DE 2940483 A1 19800430 - EGYT GYOGYSZERVEGYESZETI GYAR  
• [A] EP 0548370 A1 19930630 - MOCHIDA PHARM CO LTD [JP]  
• [A] WO 0024400 A1 20000504 - JANUS PHARMACEUTICALS INC [US], et al  
• [A] WO 02094189 A2 20021128 - VELA PHARMACEUTICALS INC [US], et al  
• [PX] US 6638928 B1 20031028 - HARRIS HERBERT W [US], et al  
• [A] TOMORI E ET AL: "Investigation of metabolites of tofizopam in man and animals", POLISH JOURNAL OF PHARMACOLOGY AND PHARMACY, POLISH ACADEMY OF SCIENCES INSTITUTE OF, PL, vol. 36, no. 4, July 1984 (1984-07-01), pages 423 - 430, XP008089223, ISSN: 0301-0244  
• See references of WO 2004069155A2

Designated contracting state (EPC)  
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

Designated extension state (EPC)  
AL LT LV MK

DOCDB simple family (publication)  
**US 2004152695 A1 20040805**; AU 2003303312 A1 20040830; AU 2003303312 A8 20040830; CA 2510275 A1 20040819; EP 1575521 A2 20050921; EP 1575521 A4 20080430; JP 2006514084 A 20060427; MX PA05005893 A 20060208; WO 2004069155 A2 20040819; WO 2004069155 A3 20060112

DOCDB simple family (application)  
**US 72817903 A 20031203**; AU 2003303312 A 20031203; CA 2510275 A 20031203; EP 03815301 A 20031203; JP 2004568017 A 20031203; MX PA05005893 A 20031203; US 0338641 W 20031203